Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Apothecary Shops Specialty Pharmacies has acquired distribution rights from Pfizer for its new drug Inlyta (axitinib).
Subscribe to our email newsletter
Inlyta (axitinib) was approved by the FDA for the treatment of advanced renal cell carcinoma (RCC) after failure of one systemic therapy.
Inlyta, an oral drug, inhibits certain receptors that can influence tumor growth and progression of kidney cancer.
The Apothecary Shops president Keith Cook said they have a first class oncology team, and the announcement reinforces their strong position in the oncology market.